Integra LifeSciences Holdings Corporation IART
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.27% | 0.76% | 2.42% | -1.74% | 5.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.27% | 0.76% | 2.42% | -1.74% | 5.57% |
| Cost of Revenue | 6.24% | -0.71% | -2.39% | 10.21% | 5.79% |
| Gross Profit | -0.71% | 1.95% | 6.17% | -9.36% | 5.41% |
| SG&A Expenses | -3.18% | -2.24% | 3.51% | 93.52% | 1.45% |
| Depreciation & Amortization | 0.80% | 0.43% | 1.94% | 1.43% | -0.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.92% | -1.16% | -0.01% | 103.48% | 1.93% |
| Operating Income | 5.47% | 23.31% | 29.57% | 58.75% | 57.17% |
| Income Before Tax | 329.54% | 100.89% | 91.98% | -80.88% | 66.49% |
| Income Tax Expenses | 157.18% | 100.56% | 146.55% | 93.63% | 85.31% |
| Earnings from Continuing Operations | 374.83% | 100.93% | 81.75% | -108.77% | 49.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 374.83% | 100.93% | 81.75% | -108.77% | 49.47% |
| EBIT | 5.47% | 23.31% | 29.57% | 58.75% | 57.17% |
| EBITDA | 3.46% | 11.45% | 15.36% | 63.96% | 27.71% |
| EPS Basic | 372.59% | 100.92% | 81.86% | -108.73% | 49.68% |
| Normalized Basic EPS | 36.47% | 71.35% | 53.63% | -37.13% | 61.07% |
| EPS Diluted | 369.89% | 100.92% | 81.86% | -109.10% | 49.71% |
| Normalized Diluted EPS | 34.42% | 69.47% | 53.63% | -37.13% | 61.07% |
| Average Basic Shares Outstanding | 0.83% | 0.78% | 0.64% | 0.47% | 0.40% |
| Average Diluted Shares Outstanding | 2.38% | 1.92% | 0.64% | 0.47% | 0.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |